Coherus Oncology declares CVR dividend tied to sale of remaining biosimilar assets

CHRS•2026-08-17

Planned sale process and financing restrictions

Coherus plans to launch a sale process for the assets, supported by an investment bank adviser.

Disposition proceeds and CVR payments are subject to restrictions under a loan agreement dated Aug. 12, 2026.

Special dividend of contingent value rights declared

Coherus Oncology declared a special dividend of non-transferable contingent value rights tied to proceeds from selling remaining legacy biosimilar assets.

CVRs go to stockholders of record at 5 p.m. New York time on Sept. 30, 2026; distribution is set for Oct. 7, 2026.

Payouts depend on net cash proceeds from any sale or monetization, including licensing fees; CVRs expire on Oct. 7, 2028.

Sources

Coherus Oncology declares CVR dividend tied to sale of remaining biosimilar assets

Sec

Coherus Oncology declares CVR dividend tied to sale of remaining biosimilar assets

Planned sale process and financing restrictions

Special dividend of contingent value rights declared

Related News

Ionic Digital backs Abbott push for responsible Texas data center growth

Ton Strategy CFO, COO Sarah Olsen disposes of 217,450 common shares for $598,502.29

NY judge tosses Uber lawsuit claiming lawyers inflated injury claims

Sources

Coherus Oncology declares CVR dividend tied to sale of remaining biosimilar assets

Hexcel EVP Chief HR & Communications Officer Gina Fitzsimons disposes of USD 996,407.11 in common shares

Clearthink 1 Acquisition delays filing quarterly report for period ended June 30, 2026